A clinical trial of a myelin basic protein (MBP) altered peptide ligand (APL) showed exacerbations in some MS patients, and further investigation showed cross-recognition between the APL and MBP driven by CD4+ T cells which were skewed towards a TH1 phenotype (45). This evidence concerns the gene MBP and myeloid sarcoma.